...read the wave
Nano Products - Nano-Produkte - Nano Producten



Evident Technologies Launches Second Generation EviTags(TM) Quantum Dot Labels to Advance Life Science Research

Unique Properties, New Surfaces to Reduce Testing Costs, Increase Flexibility and Uses


Caption: Type 2 EviTags as in vivo optical imaging agents using the dual modality Kodak4000IS optical and X-ray imaging system.

About the image:

Human prostate cancer xenografts in nude scid mice were imaged with EviTags under development using the Kodak4000IS dual modality imaging system. The NIR optical image was co-registered with the X-ray image of tumor bearing mice with and without EviTags. The strong signal attained with the EviTags show the great potential for these reagents as in vivo optical imaging agents.

TROY, N.Y., March 30 /PRNewswire/ -- Evident Technologies introduced today a second generation Type 2 EviTag(TM) luminescent label. The T2 EviTag has a proprietary natural coating that provides increased flexibility, easier use, wider applications and possible reduced testing costs in biological assays and other types of life science research.

"At Evident, we are practical pioneers developing nanomaterials to meet real needs and solve real problems," said Clint Ballinger, CEO of Evident Technologies. "Our customers need smaller, brighter, more flexible fluorescing markers to enable more applications across different life science market segments. Our T2 EviTags meet these needs and reduce testing costs because of their flexibility and adaptability. We see EviTags as an enabling technology at the crossroads of nano and bio."

EviTags are biologically-inert, conjugation-ready fluorescent labels built around a base of the company's EviDot(TM) quantum dots, which are semiconductor nanocrystals coated with a variety of patented, water- stabilizing surface treatments appropriate for a range of applications.

Type 1 EviTags feature robust and stable synthetic materials which help withstand the rigors of testing. Evident's new Type 2 EviTags offer additional benefits because of their natural surface coating, brighter fluorescence and smaller size, which makes them more suitable for fluorescent resonance energy transfer (FRET) work, live animal or in vivo imaging and molecular targeting.

"The work we are doing with Evident's tags is proving to be a first, critical stage in further exploring the inner space of cells. Clearly, we value these very bright probes as we hope to illuminate inner space," said Dr. Carl Batt, Director Cornell University-Ludwig Institute for Cancer Research Partnership, Liberty Hyde Bailey Professor of Cornell University.

Dr. Jonathan R. Slotkin, of The Brigham and Women's Hospital, Harvard Medical School said, "It has been a pleasure working with Evident Technologies' T2 EviTags in our preliminary studies labeling murine neural progenitor cells for in vitro and in vivo experimentation. We have found the T2 EviTags give robust fluorescent signal, and are remarkably stable in our culture systems. "

"In addition, we have found Evident's scientific product development and staff to be exceedingly knowledgeable, and we look forward to a continued strong working relationship with them as we move further into the use of quantum dots for in vivo transplantation experiments with neural progenitor cells in both developmental and injury models," said Dr. Slotkin.

"With their new coatings, T2 EviTags have smaller hydrodynamic radii and have been demonstrated to be efficient donors of energy transfer to acceptor dyes. The use of quantum dots in these assays will reduce, if not resolve, the laborious and time consuming data processing that is currently required to correct the bleed-through contamination between donor and acceptor dyes, making it easier and more straightforward to perform live-cell time-lapse FRET to assay the highly dynamic and transient live cellular processes. Prior to this, FRET has been hard to accomplish using traditional fluorophores to assay dynamic events in live cells," said Dr. Margarida Barroso, Assistant Professor at Albany Medical College.

Type 2 EviTags are available in seven colors from Lake Placid Blue (490nm) to Maple Red-orange (620nm), with conjugation-ready surfaces of amine, carboxyl and non-functionalized surfaces. Evident also has under development a new class of EviTags capable of advanced deep tissue imaging, as illustrated. These will be available for beta testing soon.

About Evident Technologies

Evident Technologies (http://www.evidenttech.com/) is a pioneer in the development of advanced nanomaterials engineered to enable the creation of advanced products for numerous markets including life sciences, solid state lighting, energy, security, telecommunications and emergent nanotechnology markets. Evident works with customers worldwide to fashion these advanced materials into new products and is also a leading commercial source for a wide range of quantum dot material systems that offer advantages over traditional semiconductors. For more information, visit http://www.evidenttech.com/.

Source: Evident Technologies

CONTACT: Steven Talbot, CMO, +1-518-273-6266, Evident Technologies,

Web site: http://www.evidenttech.com/

This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -


who is reading
the wave ?

missed some news ?
click on archive photo


or how about joining us


or contacting us ?


about us


our mission